Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.

Genetic testing and molecular biomarkers - 1 Jul 2015

Caner Vildan, Sen Turk Nilay, Baris Ikbal Cansu, Cetin Gokhan Ozan, Tepeli Emre, Hacioglu Sibel, Sari Ismail, Zencir Sevil, Dogu Mehmet Hilmi, Bagci Gulseren, Keskin Ali

Abstract excerpt

BACKGROUND: Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; mutations in this gene may play a role in the pathogenesis of lymphoma. AIM: We aimed to determine the MYD88 L265P mutation frequency, the level of MYD88 expression, and their associations with clinicopathological parameters in mature B-cell non-Hodgkin lymphomas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression
Share to MYD88 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Polymorphism, Single Nucleotide

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 25978699
DOI: 10.1089/gtmb.2015.0041

Genes

MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.PMID 25978699Read ↗

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.Semantic proximity Read ↗

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.Semantic proximity Read ↗

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.Semantic proximity Read ↗

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.Semantic proximity Read ↗

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.Semantic proximity Read ↗

[MyD88 L265P mutation and B cell tumor].Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.